Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

David A. Qualls, Nicholas Lambert, Paolo F. Caimi, Mwanasha Merrill, Priyanka Pullarkat, Richard C. Godby, David A. Bond, Graham T. Wehmeyer, Jason Romancik, Behzad Amoozgar, Lori Leslie, Loretta J. Nastoupil, Jennifer L. Crombie, Jeremy S. Abramson, Arushi Khurana, Grzegorz S. Nowakowski, Kami Maddocks, Sarah C. Rutherford, Brad Kahl, Michelle OkwaliMichael J. Buege, Venkatraman Seshan, Connie L. Batlevi, Gilles Salles

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

Original languageEnglish
Pages (from-to)2327-2331
Number of pages5
JournalBlood
Volume142
Issue number26
DOIs
StatePublished - Dec 28 2023

Fingerprint

Dive into the research topics of 'Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study'. Together they form a unique fingerprint.

Cite this